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Hypertrophic Cardiomyopathy
Refining the Lens of Cardiac Magnetic
Resonance to Evaluate Late
Gadolinium Enhancement*
David A. Bluemke, MD, PHD, Eunice Yang, BA
Bethesda, Maryland
Hypertrophic cardiomyopathy (HCM) is the most common
inheritable cardiomyopathy, affecting about 1 in 500 indi-
viduals. Echocardiography is most commonly used for
diagnosis and the diagnostic criteria are quite straightfor-
ward: abnormally increased thickness of the left ventricular
(LV) wall in the absence of other causes of hypertrophy.
Indeed, there are few other myocardial diseases for which
such a “simple” anatomic measurement seems sufficient for
diagnosis. However, sophisticated new imaging methods
have the potential to move well beyond anatomy alone for
the assessment of HCM.
See page 922
Cardiac magnetic resonance (CMR) can be used to assess
LV wall thickening, but the cost is 3 to 4 times more than
echocardiography. CMR physicians have long observed
HCM patients for which echocardiography did not detect
abnormal wall thickening, although the converse (echocar-
diography only detected cases) is much less likely. In a large
series of more than 300 patients, Maron et al. (1) showed
that 12% of patients had abnormal wall thickening by CMR
that was underestimated or undetected by echocardiogra-
phy. Do those “missed” cases by echocardiography matter in
terms of patient outcome, especially in regard to the greater
cost of CMR? For example, apical HCM is more likely to
be missed by echocardiography than magnetic resonance
imaging, but those patients have less frequent adverse events
than do those with outflow tract obstruction. What addi-
tional information can CMR provide?
The substrate for arrhythmia in HCM is thought to be
myocardial scar (2,3). In 2002, Choudhury et al. (4) dem-
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myocardial tissue in HCM. These late gadolinium enhance-
ment (LGE) areas on CMR reminded the investigators of
myocardial scar on postmortem specimens. Yet pathology
correlation with CMR to determine the etiology of the
enhancing areas is rare, requiring antemortem or pre-
explant CMR evaluation. Moon et al. (5) observed a single
28-year-old male who underwent CMR and cardiac trans-
plant 49 days later. O’Hanlon et al. (6) also described a
patient with CMR prior to death and autopsy. These rare
but important observations have helped to validate the
relationship between LGE tissue on CMR and myocardial
fibrosis in hypertrophic cardiomyopathy. At present, LGE/
“fibrosis” has been reported in 60% to 70% of all HCM
subjects using CMR imaging (7).
Since those early studies, LGE detected by CMR has
been rapidly investigated as a potential biomarker for
malignant arrhythmia in HCM. The presence of LGE is
more frequent in HCM patients with tachyarrhythmia
(8–10). Importantly, several studies have indicated that
LGE is an independent risk factor for adverse outcome in
HCM (6,11). Once again in HCM, could we have another
“simple” biomarker in HCM: does simply the presence of
GE (rather than the extent or pattern) place the patient at
igh risk? If LGE is present, does that risk information help
he clinical cardiologist manage the HCM patient? Al-
hough 60% to 70% of patients with a CMR will have
GE/fibrosis, the incidence of sudden cardiac death in
CM is only about 0.5% per year. Perhaps further detailed
valuation of LGE/fibrosis by CMR would be informative.
In this issue of the Journal, Todiere et al. (12) present
mportant insights regarding change of LGE over time in
CM. The authors measured focal myocardial scarring in
5 HCM patients using LGE CMR. Study subjects under-
ent two CMR scans at an average interval of about 2 years
710  410 days). The authors considered 1 g of change
in LGE mass to be statistically significant. Greater LGE/
fibrosis progression (expressed as grams per month) was
associated with a greater amount of LGE at baseline, apical
pattern of HCM, and worsening New York Heart Associ-
ation (NYHA) functional class. No correlations were noted
between LGE progression and LV mass index, LV volume,
or ejection fraction. This study demonstrates that LGE is a
late but common disease phenotype that follows the devel-
opment of hypertrophy. Interestingly, Todiere et al. (12)
also observed two patients with regression of LGE/fibrosis.
What do we know about LGE progression? In ischemic
cardiomyopathy, infarct remodeling during the first 3
months results in slight decrease in mass of the LGE tissue.
This is accompanied by tissue change of the LGE region,
from myocyte necrosis to replacement fibrosis. In contrast,
we know very little about change in LGE in nonischemic
cardiomyopathy. The study by Todiere et al. (12) thus
represents 1 of the first studies with long-term follow-up of
the LGE findings. In another study, there was no significant
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with myocarditis (13). Few other studies have addressed
change in LGE over time.
The study by Todiere et al. (12) also raises important
questions regarding quantitative imaging by CMR. The
reproducibility of quantitative CMR for most standard
measures is between 5% and 10% (14). Todiere et al. (12)
defined a threshold of LGE signal, above which LGE was
said to be present. Caution is warranted here, in that a
threshold method is likely of value only under the exact
CMR circumstances used by the authors. Common CMR
variations, such as gadolinium dose, magnetic field strength,
CMR scanner manufacturer, and pulse sequence parameters
to name but a few, have significant effects on both the
numerator (signal) and denominator (noise) of the thresh-
old. Our experience in an HCM multicenter trial suggests
that the optimal visual threshold for LGE correlates
poorly with fixed, computer-defined thresholds when
such thresholds are applied to multiple CMR centers and
manufacturers.
The incidence and rate progression of LGE observed by
Todiere et al. (12) was also almost certainly influenced by
the characteristics of the study population. There was
improvement in NYHA functional class status in 3 of 55
patients but worsened NYHA functional class in 13 patients
following medical therapy. Little information is provided
regarding concurrent medical issues as well as medications
initiated between the 2 scan times. Because the study by
Todiere et al. (12) was observational rather than interven-
tional, the medications were likely heterogeneous. Angio-
tensin II receptor blockers and angiotensin-converting en-
zyme inhibitors as well as other therapies have been
associated with regression of hypertrophy and myocardial
fibrosis in animal models as well as humans (15–18). Thus,
the relationship of medical therapy to LGE progression will
need further evaluation in subsequent studies.
In conclusion, the evidence that CMR can provide
clinically useful and distinct information apart from echo-
cardiography for HCM patients continues to increase.
Starting with the “simple” parameter of LV wall thickness,
the presence and now the progression of LGE/fibrosis may be
mportant parameters that can be tracked by CMR. Further
fforts on CMR reproducibility need to be performed, and
tandardization may eventually allow CMR physicians to
etermine useful thresholds for LGE presence or absence.
ultiple studies already point to LGE CMR as an impor-
ant biomarker to indicate adverse events in HCM. Further
tudies are needed to determine if LGE is a modifiable
arker, and if those modifications translate into better
atient outcome.Reprint requests and correspondence: Dr. David A. Bluemke,
Radiology and Imaging Sciences, Clinical Center, National Insti-
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